Standard of Care SBRT and ADT for Prostate Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
Princess Margaret Cancer Center, Toronto, Canada
Prostate Cancer+1 More
Standard of Care SBRT and ADT - OtherEligibility
18+
Male
What conditions do you have?
Select
Eligibility
18+
Male
What conditions do you have?
Select
Study Summary
This is a multi-centre, investigator-initiated, two-arm, randomized trial to investigate the addition on enzalutamide to standard of care radiation and hormone therapy improve quality of life. Participants will either receive standard of care radiation and hormone (ADT) therapy (Arm 1) or standard of care radiation and hormone (ADT) therapy plus oral enzalutamide for 8 months (Arm 2). Participants will be routinely follow-up in clinic or remotely for up to 5 years.
Eligible Conditions
- Prostate Cancer
- Malignant Neoplasms
Treatment Effectiveness
Effectiveness Progress
Other trials for Prostate Cancer
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: 5 years
5 years
Patient-reported quality of life
Physician-reported toxicity
Progression free survival
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Prostate Cancer
Trial Design
1 Treatment Group
Arm 2 - Study Treatment
1 of 1
Experimental Treatment
66 Total Participants · 1 Treatment Group
Primary Treatment: Standard of Care SBRT and ADT · No Placebo Group · Phase 2
Arm 2 - Study TreatmentExperimental Group · 2 Interventions: Standard of Care SBRT and ADT, Enzalutamide · Intervention Types: Other, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enzalutamide
2014
Completed Phase 4
~2060
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years
Closest Location: Princess Margaret Cancer Center · Toronto, Canada
2015First Recorded Clinical Trial
3 TrialsResearching Prostate Cancer
25 CompletedClinical Trials
Who is running the clinical trial?
Astellas Pharma IncIndustry Sponsor
678 Previous Clinical Trials
212,870 Total Patients Enrolled
35 Trials studying Prostate Cancer
8,635 Patients Enrolled for Prostate Cancer
University Health Network, TorontoLead Sponsor
1,351 Previous Clinical Trials
471,567 Total Patients Enrolled
63 Trials studying Prostate Cancer
15,372 Patients Enrolled for Prostate Cancer
Eligibility Criteria
Age 18+ · Male Participants · 9 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a histologic diagnosis of prostate adenocarcinoma.
You have Stage IV castrate sensitive metastatic prostate cancer.
You have one or more metastatic deposits on conventional imaging.
Additional metastases can be detectable by PSMA PET only.
All sites of disease are amenable to and can be safely treated with radiotherapy.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments